View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 17, 2022

Junshi doses first subject in Phase III Covid-19 drug trial in China

The percentage of subjects who advance to critical/severe disease or mortality within 29 days is the trial’s primary endpoint.

Shanghai Junshi Biosciences has dosed the first subject in the Phase III clinical trial of an investigational drug, VV116, to treat moderate-to-severe Covid-19. 

An oral nucleoside analog anti-SARS-CoV-2 drug, VV116 is designed to hinder virus replication. 

It is co-developed by Junshi along with Vigonvita Life Sciences.

In preclinical studies, VV116 demonstrated substantial anti-SARS-CoV-2 effects in vivo and in vitro, had increased oral bioavailability and good chemical stability.

Furthermore, the drug demonstrated to possess antiviral activity against original viral strain and key variants including Alpha, Beta, Delta and Omicron.

The global, double-blind, multicentre, randomised, controlled trial will analyse the safety and efficacy of VV116 versus standard treatment in moderate to severe Covid-19 patients. 

The percentage of subjects who advance to critical/severe Covid-19 or all-cause mortality within 29 days is the primary endpoint of the trial.

Apart from this Phase III trial, Junshi and Vigonvita commenced a global, double-blind, multicentre, randomised, placebo-controlled Phase II/III trial of VV116 in subjects with mild-to-moderate Covid-19. 

This Phase II/III trial which has currently enrolled and dosed the first participant in China, will assess the safety, efficacy and pharmacokinetics of VV116 as an early treatment for mild to moderate disease.

It has a primary endpoint identical to the Phase III trial.

According to initial data from three concluded Phase I trials analysing the safety, tolerability and pharmacokinetics of VV116 in healthy Chinese participants, the drug demonstrated to have favourable clinical safety. 

Findings from a Phase II trial of VV116 in Uzbekistan last year showed that two varying doses of the drug were found to have encouraging safety in moderate and severe Covid-19 patients versus standard treatment. 

Based on these data, VV116 obtained approval in Uzbekistan last year to treat patients with moderate to severe Covid-19.

In June 2020, Junshi dosed the first healthy subject in the Phase I trial of JS016, its SARS-CoV-2 neutralising antibody.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy